Pacific Biosciences of California Inc expected to post a loss of 17 cents a share - Earnings Preview

Pacific Biosciences of California

05/08/2025 23:12

Pacific Biosciences of California Inc PACB.OQ PACB.O is expected to  show a rise in quarterly revenue when it reports  results on August 7 for the period ending June 30 2025

The Menlo Park California-based  company is expected to report a 2.5% increase in revenue to $36.919 million from $36.01 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.The company's guidance on May 8 2025, for the period ended June 30, was for revenue of $37.153 million.

​LSEG's mean analyst estimate for Pacific Biosciences of California Inc is for a loss of 17 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $1.80, about 22.8% above its last closing price of $1.39

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.19
-0.19
-1.44
Missed
-661.9
Dec. 31 2025
-0.21
-0.21
-0.49
Missed
-138.6
Sep. 30 2024
-0.24
-0.22
-0.22
Met
2​
Jun. 30 2024
-0.24
-0.23
-0.64
Missed
-175.1
​​Mar. 31 2024
-0.28
-0.28
-0.29
Missed
-5.3
Dec. 31 2023
-0.29
-0.29
-0.31
Missed
-8.7​
Sep. 30 2023
-0.34
-0.33
-0.26
Beat
20.8
Jun. 30 2023
-0.32
-0.32
-0.28
Beat
12.7

This summary was machine generated August 5 at 22:12 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)